In two recent studies, patients with melanoma [20] or non-small cell lung cancer [21] had increased levels of Ki67+PD-1+CD8+ T cells in peripheral blood after treatment with a PD-1-targeting agent, which was considered a potential indicator of activated tumor-specific CD8+ T cells. This evidence concerns the gene PDCD1 and neoplasm.